Guselkumab, Risankizumab, and Tildrakizumab Demonstrate Parallel Effectiveness and Safety in Psoriasis Treatment: a Head-to-head Comparative Study in Real Clinical Practice
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Ruggiero A, Picone V, Martora F, Fabbrocini G, Megna M
. Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World Evidence. Clin Cosmet Investig Dermatol. 2022; 15:1649-1658.
PMC: 9392468.
DOI: 10.2147/CCID.S364640.
View
2.
Vu A, Ulschmid C, Gordon K
. Anti-IL 23 biologics for the treatment of plaque psoriasis. Expert Opin Biol Ther. 2022; 22(12):1489-1502.
DOI: 10.1080/14712598.2022.2132143.
View
3.
Torres T
. Selective Il-23 Inhibitors: The New Kids on the Block in the Treatment of Psoriasis. Actas Dermosifiliogr (Engl Ed). 2018; 109(8):674-676.
DOI: 10.1016/j.ad.2018.03.016.
View
4.
Elgaard C, Iversen L, Hjuler K
. Guselkumab, tildrakizumab, and risankizumab in a real-world setting: drug survival and effectiveness in the treatment of psoriasis and psoriatic arthritis. J Dermatolog Treat. 2022; 34(1):2133531.
DOI: 10.1080/09546634.2022.2133531.
View
5.
Reid C, Griffiths C
. Psoriasis and Treatment: Past, Present and Future Aspects. Acta Derm Venereol. 2020; 100(3):adv00032.
PMC: 9128930.
DOI: 10.2340/00015555-3386.
View